imiquimod has been researched along with Keratosis, Actinic in 155 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (7.74) | 29.6817 |
| 2010's | 107 (69.03) | 24.3611 |
| 2020's | 36 (23.23) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, AW; Kircik, LH; Rajkumar, JR | 1 |
| Farr, MA; Joshi, TP; Lewis, DJ | 1 |
| Ahmed, I; Bowden, SJ; Gaunt, C; Gaunt, P; Green, AC; Harwood, CA; Hasan, ZU; Hogan, S; Homer, V; Ismail, F; Jefferson-Hulme, Y; Kentley, J; Lear, JT; Matin, RN; Milligan, A; Mitchell-Worsford, L; Proby, CM; Thomson, J; Van-de-Velde, V; Wheatley, K; Whitmarsh, T | 1 |
| Calzavara-Pinton, I; Calzavara-Pinton, P; Rossi, M; Rovati, C | 1 |
| Ahmady, S; Arits, AHMM; de Rooij, MJM; Essers, BAB; Jansen, MHE; Kelleners-Smeets, NWJ; Kessels, JPHM; Mosterd, K; Nelemans, PJ; Quaedvlieg, PJF | 1 |
| Cheng, B; Etzkorn, JR; Giordano, CN; Higgins, HW; Miller, CJ; Shin, TM; Sobanko, JF; Veerabagu, S | 1 |
| Buján Bonino, C; López-Pardo Rico, M; Moreiras Arias, N; Pérez Feal, P; Suárez Peñaranda, JM; Vázquez Osorio, I | 1 |
| Alam, M; Anvery, N; Christensen, RE; Dirr, MA; Harikumar, V; Poon, E; Reynolds, K; Worley, B; Yi, MD | 1 |
| El-Qushayri, AE; Ghozy, S; Sakr, S; Salem, ML; Salman, S; Sarsik, SM | 1 |
| Arcuri, D; Iannattone, L; Lagacé, F; Lefrançois, P; Litvinov, IV; Netchiporouk, E; Ramchatesingh, B | 1 |
| Arthur, A; Badiavas, E; Kirsner, R; Nahm, W; Nichols, A; Rapoport, E; Shen, J; Wyant, W | 1 |
| Dirschka, T; Gollnick, H; Kerl, H; Kunstfeld, R; Ostendorf, R | 1 |
| Becker, L; Berking, C; French, LE; Heppt, MV; Kohl, C; Steeb, T | 1 |
| Marchetti, MA; Marghoob, AA; Navarrete-Dechent, C | 1 |
| Boyle, GM; Cullen, JK; Parsons, PG; Simmons, JL | 1 |
| Benati, E; Longhitano, S; Longo, C; Mirra, M; Pampena, R; Pellacani, G; Raucci, M | 1 |
| Essers, BAB; Jansen, MHE; Kelleners-Smeets, NWJ; Kessels, JPHM; Merks, I; Mosterd, K; Nelemans, PJ | 1 |
| Conforti, C; Corneli, P; di Meo, N; Dianzani, C; Farinazzo, E; Giuffrida, R; Magaton Rizzi, G; Moret, A; Zalaudek, I | 1 |
| Cantisani, C; Cantoresi, F; Mercuri, SR; Paolino, G | 1 |
| Berking, C; Heppt, MV; Steeb, T | 1 |
| Asinari, J; Feliciani, C; Goldust, M; Lotti, T; Pedrazzi, G; Satolli, F; Zucchi, A | 1 |
| Kopera, D | 1 |
| Ali, FR; Raza, SA | 1 |
| Dunkelly-Allen, N; Feldman, SR; Hansen, JB; Larsson, T; Veverka, KA | 1 |
| Baker, C; MacMahon, B; Sinclair, R; Spelman, L; Supranowicz, M | 1 |
| Brignone, M; Ezzedine, K; Painchault, C | 1 |
| Feldman, SR; Heron, CE | 1 |
| Ahmady, S; Essers, BAB; Jansen, MHE; Kelleners-Smeets, NWJ; Kessels, JPHM; Mosterd, K; Nelemans, PJ | 1 |
| Castagnetti, E; Cortelazzi, C; Di Nuzzo, S; Odorici, G; Pellacani, G | 1 |
| Asgari, MM; Bennett, DD; Connolly, SM; Dellavalle, RP; Eisen, DB; Frazer-Green, L; Freeman, EE; Goldenberg, G; Leffell, DJ; Malik, S; Peschin, S; Schlesinger, TE; Sligh, JE; Wu, PA | 2 |
| Berking, C; Brinker, TJ; Heppt, MV; Petzold, A; Schmitz, L; Schöffski, O; Steeb, T; Wessely, A | 1 |
| Chang, R; Fullerton, BT; Gartrell, R; Geskin, LJ; Goldenberg, G; Lau, B; Moore, M; Pradhan, J; Rizk, E; Rose, S; Saenger, YM; Singer, G; Srivastava, AC; Trager, MH; Zhu, K | 1 |
| Fujio, Y; Konohana, I; Kurihara, Y; Tanaka, R; Tanese, K; Zhu, Y | 1 |
| Cull, D; Emmerich, VK; Feldman, SR; Kelly, KA | 1 |
| Berking, C; Brinker, TJ; Garbe, C; Heppt, MV; Leiter, U; Petzold, A; Schmitz, L; Schöffski, O; Steeb, T; Wessely, A | 1 |
| Carr, DR; Kaffenberger, JA; Yanes, DA | 1 |
| Funasaka, Y; Kawana, S; Oyama, S; Saeki, H; Tsuchiya, SI | 1 |
| Athanasakis, K; Boubouchairopoulou, N; Kontodimas, S; Kyriopoulos, J; Tarantilis, F; Tsiantou, V | 1 |
| Holmstrup, H; Jemec, GBE; Malmberg, I; Norlin, JM; Norrlid, H; Ragnarson Tennvall, G; Sartorius, K; Thormann, H | 1 |
| Gonzalez, H; Haedersdal, M; Halldin, C; Sandberg, C; Sørensen, SS; Togsverd-Bo, K; Wennberg, AM; Wulf, HC | 1 |
| Salido Vallejo, R | 1 |
| Calomarde, L; Guillén, C; Llombart, B; Nagore, E; Requena, C; Sanmartín, O; Serra-Guillén, C | 1 |
| Kaneda, K; Kokunai, Y; Kurokawa, T; Moriwaki, S; Otsuka, T; Sugimoto, A; Tanizaki, H; Yu, A | 1 |
| Asgari, MM; Chren, MM; Friedman, GD; Levandoski, KA; Neugebauer, R; Sokil, M; Zhu, Z | 1 |
| Fridman, A; Fridman, G; Friedman, PC; Miller, V | 1 |
| Ibbotson, SH | 1 |
| Fernández-Orland, A; Ferrándiz, L; Martín-Gutiérrez, FJ; Morales-Conde, M; Moreno-Ramírez, D; Raya-Maldonado, J; Toledo-Pastrana, T | 1 |
| da Motta, VRV; de Oliveira, ECV; Galadari, H; Ilha, CSO; Leonardi, GR; Magalhães, RF; Pantoja, PC | 1 |
| Sayama, K; Shiraishi, K | 1 |
| Calzavara-Pinton, P; Hamon, P; Tanova, N | 1 |
| Borgia, F; Cannavò, SP; Giuffrida, R | 1 |
| Asgari, MM; Chren, MM; Friedman, GD; Neugebauer, R; Sokil, M; Su, KA; Zhu, Z | 1 |
| Katare, OP; Sharma, G; Sharma, M; Singh, B | 1 |
| Antoniou, C; Befon, A; Chasapi, V; Panagiotopoulos, A; Stratigos, AJ; Tzanetakou, V | 1 |
| Landucci, G; Savoia, P; Tarantino, V; Veronese, F; Zavattaro, E | 1 |
| Arits, AHMM; Essers, BAB; Jansen, MHE; Kelleners-Smeets, NWJ; Kessels, JPHM; Kouloubis, N; Mosterd, K; Nelemans, PJ; Quaedvlieg, PJF; Steijlen, PM; van Pelt, HPA | 1 |
| Igari, S; Ohtsuka, M; Yamamoto, T | 1 |
| Herms, F | 1 |
| Dréno, B; Paugam, C | 1 |
| Bhatia, N; Chen, T; Hashim, PW; Kircik, LH; Rigel, D | 1 |
| Kircik, LH | 1 |
| Borik, L; Brunner, PM; Geusau, A; Mildner, M; Müllegger, R; Petzelbauer, P; Tzaneva, S | 1 |
| Beer, HD; Belloni, B; Bloch, W; Cecconi, V; Dummer, R; Knuth, A; Matter, C; Schäfer, M; Schönewolf, N; Urosevic-Maiwald, M; van den Broek, M; Walter, A; Werner, S | 1 |
| Berneburg, MJ; Eigentler, TK; Garbe, C; Held, L; Leiter, U | 1 |
| Gupta, AK; Paquet, M | 1 |
| Cockerell, CJ; Samrao, A | 1 |
| Calzavara Pinton, P; Catricalà, C; Neri, L; Pellacani, G; Peris, K; Peserico, A; Pimpinelli, N | 2 |
| Banzhaf, CA; Jemec, GB; Mogensen, M; Ring, HC; Themstrup, L | 1 |
| Furumura, M; Hashimoto, T; Imamura, K; Ishii, N; Kawakami, T; Ohata, C; Tanaka, N; Tsuruta, D; Ueda, A; Yasumoto, S | 1 |
| Goldenberg, G; Kaur, M; Smith, CC; Swanson, N | 2 |
| Elsner, P; Goetze, S; Kalampalikis, A | 1 |
| Cavicchini, S; Chimenti, S; Javor, S; Parodi, A; Patrizi, A; Pellacani, G; Rongioletti, F; Sala, R; Stingeni, L | 1 |
| Bauer, A; Elsner, P; Schliemann, S | 1 |
| Kerl, H; Kopera, D | 2 |
| Aoki, R; Kawamura, T; Matsuzawa, T; Ogawa, Y; Shimada, S | 1 |
| Altamura, D; Arkoumani, E; Hirbod, T; Simonacci, F; Verdolini, R | 1 |
| Alomar, A; Aractingi, S; Dakovic, R; Dirschka, T; Gupta, G; Peris, K; Stockfleth, E | 4 |
| Sligh, JE | 1 |
| Stockfleth, E | 3 |
| Gupta, G | 1 |
| Fargnoli, MC; Peris, K | 1 |
| Philipp-Dormston, WG | 1 |
| Knackstedt, TJ; Quitadamo, M | 1 |
| Gaastra, MT; Hollestein, LM; Holterhues, C; Kuijpers, DI; Nijsten, TE; Schuttelaar, ML; van Hattem, S; Waalboer-Spuij, R | 1 |
| Guo, F; Lei, M; Li, N; Ma, M; Tan, F; Wang, J | 1 |
| Alarcon, I; Sibbring, GC; Stockfleth, E | 1 |
| Isoherranen, K; Koskenmies, S; Overmark, M; Pitkänen, S; Saksela, O; Ylitalo, L | 1 |
| Egekvist, H; Erlendsson, AM; Haedersdal, M; Lorentzen, HF; Philipsen, PA; Stausbøl-Grøn, B; Stender, IM | 1 |
| Alkemade, HA; Gerritsen, MJ; Groenewoud, H; Grutters, JP; Maessen-Visch, MB; Seubring, I; van de Kerkhof, PC; van der Wilt, GJ; van Doorn, R; van Rijsingen, MC | 1 |
| Erdmann, R; Jacobs, A; Nast, A; Rosumeck, S; Sporbeck, B; Werner, RN | 1 |
| Capizzi, R; Fargnoli, MC; Peris, K; Tambone, S | 1 |
| Aires, D; Cullan, J; Hogan, K; Isedeh, P | 1 |
| Araki, Y; Arima, M; Iwata, Y; Kobayashi, T; Matsunaga, K; Numata, S; Okamura, K; Sugiura, K; Suzuki, T; Yagami, A | 1 |
| Abadi, R; Abbas, O; Hanna, E | 1 |
| Kawada, A; Narita, T; Oiso, N | 1 |
| Basset-Séguin, N; Del Marmol, V; Dirschka, T; Dummer, R; Gupta, G; Jemec, GBE; Malvehy, J; Micali, G; Pellacani, G; Peris, K; Puig, S; Stockfleth, E; Stratigos, AJ; Zalaudek, I | 1 |
| Itenberg, S; Lebwohl, M; Stern, DW; Uliasz, A; Zeichner, JA | 1 |
| Dahiya, M; Jessup, C; Reynolds, R; Yang, FC | 1 |
| French, LE; Hofbauer, GF; Koch, S; Läuchli, S; Pini, AM; Schärer, L | 1 |
| Shaffelburg, M | 1 |
| Ulrich, C | 1 |
| Downs, A; Muston, D; Rives, V | 1 |
| Apalla, Z; Ioannides, D; Maliamani, F; Panagiotidou, D; Sotiriou, E; Zaparas, N | 1 |
| Balmer, N; Conde, J; Davis, K; Jones, D; McMichael, A; Ntuen, E | 1 |
| A Gaspari, A; Rosen, T; Tyring, SK | 1 |
| Cowen, PS; Gebauer, K; Shumack, S | 1 |
| Astner, S; Krueger-Corcoran, D; Roewert-Huber, J; Sterry, W; Stockfleth, E; Ulrich, M | 1 |
| Barbuzza, O; Guarneri, B; Vaccaro, M | 1 |
| Beer, KR; Hanke, CW; Levy, S; Rosen, T; Stockfleth, E; Wu, J | 1 |
| Abramovits, W; Berman, B; Kulp, J; Levy, S; Rigel, DS; Swanson, N | 1 |
| Duteil, L; Gupta, G; Mallefet, P; Ortonne, JP; Ortonne, N; Queille, C | 1 |
| Adams, M; Fein, MC; Furst, J; Kulp, J; Levy, S; Meng, TC | 1 |
| Collins, C; Harrad, RA; Kennedy, CT; Ross, AH | 1 |
| Dinotta, F; Lacarrubba, F; Massimino, D; Micali, G; Nasca, MR | 1 |
| Kemény, L; Nagy, N | 1 |
| Muhn, C; Rosen, N; Shoimer, I | 1 |
| Adam, F; Fenske, NA; Spencer, J | 1 |
| Taeron, C | 1 |
| Burnett, TJ; English, JC; Ferris, LK | 1 |
| Braga, JC; Busam, K; Dusza, SW; Gill, M; Halpern, AC; Marghoob, AA; Scope, A; Terushkin, V | 1 |
| Cannon, PS; Huilgol, SC; O'Donnell, B; Selva, D | 1 |
| Barr, KL; Fung, MA; Konia, TH | 1 |
| Bourcier, M; Jorizzo, JL; Kulp, J; Lebwohl, MG; Levy, S; Markowitz, O; Meng, TC | 1 |
| Chimenti, S; Colombo, GL; Di Matteo, S; Fargnoli, MC; Frascione, P; Peris, K; Silipo, V | 1 |
| Wilson, EC | 1 |
| Botella-Estrada, R; Guillen, C; Hueso, L; Llombart, B; Nagore, E; Requena, C; Sanmartín, O; Serra-Guillen, C | 1 |
| Levine, VJ; Machler, BC; Mark, NM; Patel, U | 1 |
| Gollnick, HP; Quist, SR | 1 |
| Berman, B; Bruce, S; Hanke, CW; Kulp, J; Levy, S; Swanson, N | 1 |
| Clark, AR; Huang, WW | 1 |
| Gaspari, AA; Grossberg, AL | 1 |
| Frankel, A; Goldenberg, G | 1 |
| Akarsu, S; Aktan, S; Atahan, A; Koç, P; Özkan, S | 1 |
| Chan, MP; Zimarowski, MJ | 1 |
| Akkilic-Materna, M; Komericki, P; Massone, C | 1 |
| Heikkinen, AK; Susitaival, P | 1 |
| Cahill, J; Campbell, J; Crouch, R; Cumming, S; Foley, P; Harrison, S; Merlin, K | 1 |
| Botella-Estrada, R; Guillén, C; Hueso, L; Llombart, B; Messeguer, F; Nagore, E; Requena, C; Sanmartín, O; Serra-Guillén, C; Traves, V | 1 |
| Ergin, S; Kaçar, N; Sanli, B; Yildiz, N; Zalaudek, I | 1 |
| Cotter, M; Florell, S; Hadley, J; Hadley, M; Hull, C; Tristani-Firouzi, P | 1 |
| Kerl, H; Schuster, L; Strohal, R | 1 |
| Cockerell, CJ; Kerner, JD; Miedler, JD; Mings, SM; Ondo, AL; Padilla, RS; Shanler, SD; Steiner, RL | 1 |
| Brodell, RT; Tandon, Y | 1 |
| Esmann, S; Jemec, GB | 1 |
| Idezuki, T | 1 |
| Anders, M; Birmachu, W; Bulbulian, BJ; Jin, J; Lee, J; Miller, RL; Raghavan, S; Slade, HB; Storey, L; Torres, A | 1 |
38 review(s) available for imiquimod and Keratosis, Actinic
| Article | Year |
|---|---|
INDIVIDUAL ARTICLE: Safety and Tolerability of Topical Agents for Actinic Keratosis: A Systematic Review of Phase 3 Clinical Trials.
Topics: Administration, Topical; Cryotherapy; Diterpenes; Humans; Imiquimod; Keratosis, Actinic; Treatment Outcome | 2021 |
Topical Pharmacotherapy for Actinic Keratoses in Older Adults.
Topics: Aged; Diclofenac; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Treatment Outcome | 2022 |
Treatment of actinic keratosis: a systematic review.
Topics: Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Skin Neoplasms; Treatment Outcome | 2023 |
Safety and efficacy of the combination of cryotherapy and photodynamic modalities with imiquimod in patients with actinic keratosis: a systematic review and meta-analysis.
Topics: Aminoquinolines; Cryotherapy; Humans; Imiquimod; Keratosis, Actinic; Treatment Outcome | 2023 |
Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review.
Topics: Aminolevulinic Acid; Diclofenac; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Photosensitizing Agents; Treatment Outcome | 2023 |
Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials.
Topics: Adjuvants, Immunologic; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Diclofenac; Facial Neoplasms; Female; Gels; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp; Skin Cream | 2020 |
Topical treatments for skin cancer.
Topics: Administration, Cutaneous; Antineoplastic Agents; Carcinoma, Basal Cell; Clinical Trials as Topic; Diterpenes; Drug Delivery Systems; Fluorouracil; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Keratosis, Actinic; Melanoma; Neoplasms, Squamous Cell; Photochemotherapy; Retinoids; Skin; Skin Neoplasms; Ultraviolet Rays | 2020 |
Current therapies for actinic keratosis.
Topics: Aftercare; Carcinoma, Squamous Cell; Chemexfoliation; Cryotherapy; Curettage; Dermoscopy; Diclofenac; Disease Progression; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Laser Therapy; Photochemotherapy; Practice Guidelines as Topic; Protective Clothing; Skin; Skin Neoplasms; Sunlight; Sunscreening Agents | 2020 |
A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies.
Topics: Antineoplastic Agents; Diclofenac; Disease Progression; Diterpenes; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Recurrence; Skin Neoplasms | 2021 |
Systematic Literature Review and Network Meta-analysis of the Efficacy and Acceptability of Interventions in Actinic Keratoses.
Topics: Diterpenes; Humans; Imiquimod; Keratosis, Actinic; Network Meta-Analysis; Photochemotherapy; Treatment Outcome | 2021 |
Guidelines of care for the management of actinic keratosis.
Topics: Diclofenac; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy | 2021 |
Long-term recurrence rates of actinic keratosis: A systematic review and pooled analysis of randomized controlled trials.
Topics: Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Randomized Controlled Trials as Topic | 2022 |
Guidelines of care for the management of actinic keratosis: Executive summary.
Topics: Cryosurgery; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Practice Guidelines as Topic | 2021 |
Evaluation of Long-term Clearance Rates of Interventions for Actinic Keratosis: A Systematic Review and Network Meta-analysis.
Topics: Cryosurgery; Humans; Imiquimod; Keratosis, Actinic; Network Meta-Analysis; Photochemotherapy; Randomized Controlled Trials as Topic | 2021 |
Erythema multiforme as a reaction to imiquimod 5% cream.
Topics: Adjuvants, Immunologic; Aminoquinolines; Erythema Multiforme; Glucocorticoids; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp Dermatoses | 2017 |
Actinic keratosis - review for clinical practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cryotherapy; Diclofenac; Diterpenes; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Retinoids | 2019 |
Actinic keratosis and imiquimod: a review of novel carriers and patents.
Topics: Adjuvants, Immunologic; Humans; Imiquimod; Keratosis, Actinic; Patient Compliance; Skin | 2019 |
Actinic Keratosis: Current Therapies and Insights Into New Treatments
Topics: Cryosurgery; Dermatologic Agents; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy | 2019 |
Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review.
Topics: Adjuvants, Immunologic; Aged; Aminolevulinic Acid; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Cryotherapy; Diclofenac; Diterpenes; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Hyaluronic Acid; Imiquimod; Immunocompetence; Immunosuppressive Agents; Keratosis, Actinic; Male; Middle Aged; Photochemotherapy; Photosensitizing Agents; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents.
Topics: Administration, Topical; Aminoquinolines; Cryotherapy; Diclofenac; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Imiquimod; Keratosis, Actinic; Male; Photochemotherapy; Precancerous Conditions; Severity of Illness Index; Treatment Outcome | 2013 |
New therapeutic options for actinic keratosis and basal cell carcinoma.
Topics: Aminoquinolines; Anilides; Antineoplastic Agents; Carcinoma, Basal Cell; Cryosurgery; Diterpenes; Humans; Imiquimod; Keratosis, Actinic; Mutation; Patched Receptors; Pyridines; Receptors, Cell Surface; Skin Neoplasms; Treatment Outcome | 2014 |
Lmax and imiquimod 3.75%: the new standard in AK management.
Topics: Adjuvants, Immunologic; Aminoquinolines; Humans; Imiquimod; Keratosis, Actinic | 2015 |
Conventional treatment of actinic keratosis: an overview.
Topics: Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cryotherapy; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy | 2015 |
New Topical Treatment Options for Actinic Keratosis: A Systematic Review.
Topics: Administration, Cutaneous; Aminoquinolines; Dermatologic Agents; Diterpenes; Drug Combinations; Facial Dermatoses; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Randomized Controlled Trials as Topic; Salicylic Acid; Scalp Dermatoses; Skin; Treatment Outcome | 2016 |
[Diagnosis and treatment of actinic keratosis].
Topics: Administration, Topical; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cryotherapy; Diclofenac; Diterpenes; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Laser Therapy; Photochemotherapy; Precancerous Conditions; Primary Health Care | 2015 |
Imiquimod in dermatology: an overview.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Carcinoma, Basal Cell; Condylomata Acuminata; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Prognosis; Skin Diseases; Skin Neoplasms; Treatment Outcome | 2016 |
Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology.
Topics: Algorithms; Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Cryotherapy; Disease Progression; Humans; Imiquimod; Keratosis, Actinic; Laser Therapy | 2017 |
Actinic keratoses.
Topics: Aged; Aminoquinolines; Carcinoma, Squamous Cell; Cryotherapy; Dermatology; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Lasers; Medical Oncology; Models, Biological; Organ Transplantation; Photochemotherapy; Retinoids; Skin Neoplasms | 2009 |
Topical treatment of field cancerization.
Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Diclofenac; Fluorouracil; Humans; Imiquimod; Immunosuppression Therapy; Immunosuppressive Agents; Keratosis, Actinic; Organ Transplantation; Photochemotherapy; Recurrence; Skin Neoplasms; Tissue Distribution | 2009 |
Beyond a decade of 5% imiquimod topical therapy.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Condylomata Acuminata; Humans; Imiquimod; Keratosis, Actinic; Papillomavirus Infections; Skin Diseases; Skin Neoplasms; Toll-Like Receptor 7 | 2009 |
Treating skin cancer with topical cream.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Diclofenac; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Retinoids; Skin Neoplasms | 2010 |
[New perspective in immunotherapy: local imiquimod treatment].
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antiviral Agents; Carcinoma, Basal Cell; Condylomata Acuminata; Dendritic Cells; Humans; Imiquimod; Immunity, Innate; Keratosis, Actinic; Langerhans Cells; Off-Label Use; Skin Neoplasms; Toll-Like Receptor 7; Toll-Like Receptor 8; Toll-Like Receptors | 2010 |
Actinic keratoses: past, present and future.
Topics: Adjuvants, Immunologic; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Cryosurgery; Diclofenac; Fluorouracil; Humans; Imiquimod; Immunosuppressive Agents; Keratosis, Actinic; Photochemotherapy; Precancerous Conditions; Skin Neoplasms | 2010 |
Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism.
Topics: Adjuvants, Immunologic; Aged; Aminoquinolines; Anti-Inflammatory Agents; Biopsy; Clobetasol; Humans; Imiquimod; Keratosis, Actinic; Male; Psoriasis; Treatment Outcome; Ultraviolet Therapy | 2011 |
Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Combined Modality Therapy; Cryosurgery; Drug Administration Schedule; Face; Humans; Imiquimod; Keratosis, Actinic; Medication Adherence; Scalp | 2011 |
Topical antineoplastic agents in the treatment of mucocutaneous diseases.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Diterpenes; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Mucositis; Mucous Membrane; Skin Diseases; Skin Neoplasms | 2011 |
Local reactions to imiquimod in the treatment of basal cell carcinoma.
Topics: Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Humans; Imiquimod; Keratosis, Actinic; Neoplasm Recurrence, Local; Skin Neoplasms; Treatment Outcome | 2012 |
[Field cancerization and field therapy - the therapy of actinic keratosis by imiquimod].
Topics: Aminoquinolines; Cell Transformation, Neoplastic; Humans; Imiquimod; Keratosis, Actinic; Toll-Like Receptors | 2013 |
35 trial(s) available for imiquimod and Keratosis, Actinic
| Article | Year |
|---|---|
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).
Topics: Carcinoma, Squamous Cell; Feasibility Studies; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Organ Transplantation; Sunscreening Agents; Transplant Recipients; Treatment Outcome | 2022 |
Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; Skin Neoplasms; Treatment Outcome | 2022 |
A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherla
Topics: Aminolevulinic Acid; Cost-Benefit Analysis; Diterpenes; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Netherlands; Photochemotherapy; Photosensitizing Agents; Prospective Studies; Treatment Outcome | 2020 |
The Effect of Four Approaches to Treat Actinic Keratosis on the Health-Related QOL, as Assessed by the Skindex-29 and Actinic Keratosis QOL.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Diterpenes; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; Patient Reported Outcome Measures; Photochemotherapy; Quality of Life; Skin Cream; Surveys and Questionnaires; Treatment Outcome | 2021 |
Comparative study of imiquimod 3.75% vs. photodynamic therapy for actinic keratosis of the scalp.
Topics: Aminolevulinic Acid; Humans; Imiquimod; Keratosis, Actinic; Male; Photochemotherapy; Photosensitizing Agents; Pilot Projects; Scalp; Treatment Outcome | 2021 |
Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients: a randomized intraindividual controlled trial.
Topics: Aged; Aminolevulinic Acid; Drug Eruptions; Facial Dermatoses; Female; Hand Dermatoses; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Pain; Photochemotherapy; Photosensitizing Agents; Scalp Dermatoses; Treatment Outcome | 2018 |
A 12-Day Course of Imiquimod 5% for the Treatment of Actinic Keratosis: Effectiveness and Local Reactions.
Topics: Aged; Aged, 80 and over; Female; Humans; Imiquimod; Interferon Inducers; Keratosis, Actinic; Male; Time Factors; Treatment Outcome | 2018 |
Teledermatology-driven topical therapy of actinic keratosis: a comparative study of clinical effectiveness and compliance.
Topics: Administration, Cutaneous; Aged; Antineoplastic Agents; Facial Dermatoses; Female; Humans; Imiquimod; Intention to Treat Analysis; Keratosis, Actinic; Longitudinal Studies; Male; Medication Adherence; Office Visits; Prospective Studies; Telemedicine | 2018 |
Imiquimod 3.75% for field-directed therapy of actinic keratosis: results of a prospective case-series study in Greece.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aged, 80 and over; Drug Administration Schedule; Face; Female; Greece; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Prospective Studies; Skin; Sunlight; Treatment Outcome | 2019 |
Randomized Trial of Four Treatment Approaches for Actinic Keratosis.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Diterpenes; Female; Fluorouracil; Follow-Up Studies; Gels; Humans; Imiquimod; Intention to Treat Analysis; Keratosis, Actinic; Male; Middle Aged; Patient Compliance; Photochemotherapy; Photosensitizing Agents; Proportional Hazards Models; Scalp Dermatoses; Single-Blind Method; Skin Cream; Treatment Outcome | 2019 |
Peptidase inhibitor 3 and chemokine ligand 27 may serve as biomarkers for actinic keratoses in organ transplant recipients.
Topics: Administration, Topical; Aged; Aminolevulinic Acid; Biomarkers; Chemokine CCL27; Elafin; Female; Follow-Up Studies; Gene Expression Regulation; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Photochemotherapy; Prospective Studies; Reference Values; RNA, Messenger; Severity of Illness Index; Transplant Recipients; Treatment Outcome | 2019 |
Effective combination of photodynamic therapy and imiquimod 5% cream in the treatment of actinic keratoses: three cases.
Topics: Adjuvants, Immunologic; Adult; Aged, 80 and over; Aminoquinolines; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Ointments; Skin; Time Factors | 2013 |
Optical coherence tomography imaging of non-melanoma skin cancer undergoing imiquimod therapy.
Topics: Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Melanoma; Prognosis; Reproducibility of Results; Sensitivity and Specificity; Skin Neoplasms; Tomography, Optical Coherence; Treatment Outcome | 2014 |
Comparative study for the effect of photodynamic therapy, imiquimod immunotherapy and combination of both therapies on 40 lesions of actinic keratosis in Japanese patients.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aminoquinolines; Female; Humans; Imiquimod; Japan; Keratosis, Actinic; Male; Middle Aged; Photochemotherapy; Treatment Outcome | 2013 |
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aminoquinolines; Dose-Response Relationship, Drug; Double-Blind Method; Face; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp; Treatment Outcome | 2013 |
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Topics: Adjuvants, Immunologic; Adult; Aminoquinolines; Dose-Response Relationship, Drug; Double-Blind Method; Face; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp; Skin Aging; Treatment Outcome | 2014 |
Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aminoquinolines; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Face; Female; Follow-Up Studies; Humans; Imiquimod; Keratosis, Actinic; Male; Scalp; Severity of Illness Index; Skin; Time Factors; Treatment Outcome | 2015 |
Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Double-Blind Method; Face; Facial Dermatoses; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp; Scalp Dermatoses; Severity of Illness Index; Treatment Outcome | 2015 |
Patient Perception of Imiquimod Treatment for Actinic Keratosis and Superficial Basal Cell Carcinoma in 202 Patients.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Patient Satisfaction; Quality of Life; Skin Cream; Skin Neoplasms; Surveys and Questionnaires | 2015 |
Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses.
Topics: Adjuvants, Immunologic; Aged; Aminoquinolines; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Pharmaceutical Preparations; Pilot Projects; Time Factors | 2009 |
Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aminoquinolines; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Photochemotherapy; Photosensitizing Agents; Pilot Projects | 2009 |
Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities.
Topics: Administration, Topical; Aged; Aminolevulinic Acid; Aminoquinolines; Dose-Response Relationship, Drug; Female; Humans; Imiquimod; Interferon Inducers; Keratosis, Actinic; Male; Middle Aged; Ointments; Patient Satisfaction; Photochemotherapy; Photosensitizing Agents; Treatment Outcome; Upper Extremity | 2009 |
Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aminoquinolines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Forearm; Hand Dermatoses; Humans; Imiquimod; Keratosis, Actinic; Male; Precancerous Conditions; Treatment Outcome | 2009 |
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Dosage Forms; Double-Blind Method; Drug Administration Schedule; Face; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp; Time Factors | 2010 |
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Dosage Forms; Double-Blind Method; Drug Administration Schedule; Face; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp; Time Factors | 2010 |
Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Double-Blind Method; Female; Fluorescence; Humans; Imiquimod; Keratosis, Actinic; Levulinic Acids; Light; Male; Middle Aged; Photography; Photosensitizing Agents | 2010 |
Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp.
Topics: Aged; Aged, 80 and over; Alopecia; Aminoquinolines; Face; Female; Half-Life; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp; Skin | 2010 |
A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses.
Topics: Adult; Aged; Aged, 80 and over; Aminoquinolines; Combined Modality Therapy; Cross-Over Studies; Cryosurgery; Double-Blind Method; Female; Humans; Imiquimod; Immunosuppressive Agents; Keratosis, Actinic; Male; Middle Aged; Ointments; Socioeconomic Factors | 2010 |
A randomized comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolaevulinate.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aminolevulinic Acid; Aminoquinolines; Child; Child, Preschool; Facial Dermatoses; Female; Humans; Imiquimod; Infant; Keratosis, Actinic; Male; Middle Aged; Patient Satisfaction; Photochemotherapy; Photosensitizing Agents; Scalp Dermatoses; Young Adult | 2011 |
Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream.
Topics: Adult; Aminoquinolines; Double-Blind Method; Drug Administration Schedule; Face; Humans; Imiquimod; Keratosis, Actinic; Male; Scalp; Time Factors; Treatment Outcome | 2011 |
Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Diclofenac; Female; Gels; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Ointments; Single-Blind Method; Skin Neoplasms; Treatment Outcome | 2011 |
A comparison of cryotherapy and imiquimod for treatment of actinic keratoses: lesion clearance, safety, and skin quality outcomes.
Topics: Adjuvants, Immunologic; Aged; Aminoquinolines; Cryotherapy; Facial Dermatoses; Female; Follow-Up Studies; Humans; Imiquimod; Keratosis, Actinic; Male; Scalp Dermatoses; Treatment Outcome | 2011 |
A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes.
Topics: Administration, Topical; Aged; Aminolevulinic Acid; Aminoquinolines; Female; Humans; Imiquimod; Immunocompetence; Keratosis, Actinic; Male; Photochemotherapy; Photosensitizing Agents; Pilot Projects; Prospective Studies; Treatment Outcome | 2012 |
Results of an investigator-initiated single-blind split-face comparison of photodynamic therapy and 5% imiquimod cream for the treatment of actinic keratoses.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Aminoquinolines; Facial Dermatoses; Humans; Imiquimod; Interferon Inducers; Keratosis, Actinic; Male; Middle Aged; Photochemotherapy; Quality of Life; Single-Blind Method; Treatment Outcome | 2012 |
Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.
Topics: Adaptive Immunity; Adjuvants, Immunologic; Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Apoptosis; Cell Proliferation; Chemokines; Demography; Dendritic Cells; Dosage Forms; Gene Expression Profiling; Gene Expression Regulation; Humans; Imiquimod; Immunity, Innate; Interferon Type I; Keratosis, Actinic; Killer Cells, Natural; Macrophages; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Receptors, Pattern Recognition; Reproducibility of Results; T-Lymphocytes, Cytotoxic | 2007 |
82 other study(ies) available for imiquimod and Keratosis, Actinic
| Article | Year |
|---|---|
Resiquimod: a new topical immune-response modifier for the treatment of actinic keratosis.
Topics: Adjuvants, Immunologic; Humans; Imidazoles; Imiquimod; Keratosis, Actinic | 2021 |
A comparison of invasive squamous cell carcinoma greater than 1 year after treatment with 5-fluorouracil, imiquimod, or photodynamic therapy with aminolevulinic acid.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Photosensitizing Agents; Prospective Studies; Retrospective Studies; Skin Neoplasms; Treatment Outcome | 2022 |
Lupus-like reaction following imiquimod treatment for actinic keratoses.
Topics: Adjuvants, Immunologic; Aminoquinolines; Humans; Imiquimod; Keratosis, Actinic; Treatment Outcome | 2022 |
Keratinocyte Carcinoma Chemoprevention With a Combination of Imiquimod, 5-Fluorouracil, and Tretinoin.
Topics: Carcinoma, Squamous Cell; Chemoprevention; Fluorouracil; Humans; Imiquimod; Keratinocytes; Keratosis, Actinic; Prospective Studies; Treatment Outcome; Tretinoin | 2023 |
Long-term efficacy of interventions for actinic keratosis: protocol for a systematic review and network meta-analysis.
Topics: Adjuvants, Immunologic; Disease Progression; Diterpenes; Europe; Humans; Imiquimod; Keratosis, Actinic; Meta-Analysis as Topic; Network Meta-Analysis; Photochemotherapy; Randomized Controlled Trials as Topic; Systematic Reviews as Topic | 2019 |
Contemporary management of actinic keratosis.
Topics: Carcinoma, Squamous Cell; Cryotherapy; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms | 2021 |
Digital follow-up by means of dermatoscopy and reflectance confocal microscopy of actinic keratosis treated with Imiquimod 3.75% cream.
Topics: Aminoquinolines; Dermoscopy; Follow-Up Studies; Humans; Imiquimod; Keratosis, Actinic; Microscopy, Confocal; Sweden; Treatment Outcome | 2020 |
Clinical evaluation and efficacy of Imiquimod 3.75% cream for the treatment of actinic keratosis, pigmented basal cell carcinomas, and actinic cheilitis.
Topics: Adjuvants, Immunologic; Aminoquinolines; Carcinoma, Basal Cell; Cheilitis; Humans; Imiquimod; Keratosis, Actinic; Skin Neoplasms | 2020 |
Cash is king: the balance of costs and effectiveness of treatments for actinic keratosis.
Topics: Aminolevulinic Acid; Cost-Benefit Analysis; Diterpenes; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Netherlands; Photochemotherapy | 2020 |
Actinic keratosis: Treatment with imiquimod 3.75%-A comparative study between patients with previous in situ melanoma, patients with invasive melanoma and patients with negative history of melanoma.
Topics: Aminoquinolines; Humans; Imiquimod; Keratosis, Actinic; Melanoma; Skin Neoplasms | 2020 |
Earliest stage treatment of actinic keratosis with imiquimod 3.75% cream: Two case reports-Perspective for non melanoma skin cancer prevention.
Topics: Aged, 80 and over; Aminoquinolines; Child, Preschool; Female; Humans; Imiquimod; Infant; Keratosis, Actinic; Middle Aged; Skin Neoplasms; Treatment Outcome | 2020 |
Comparison of efficacy of field treatments for actinic keratoses.
Topics: Adult; Aminolevulinic Acid; Diterpenes; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Scalp Dermatoses | 2020 |
Real-World Effectiveness and Safety of Field- and Lesion-Directed Treatments for Actinic Keratosis.
Topics: Administration, Cutaneous; Aged; Antineoplastic Agents; Combined Modality Therapy; Cryotherapy; Diterpenes; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Skin; Treatment Outcome; United States | 2020 |
Ingenol Mebutate and the Treatment of Actinic Keratosis.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Clinical Trials as Topic; Diterpenes; Fluorouracil; Humans; Imiquimod; Incidence; Keratosis, Actinic; Patient Preference; Photochemotherapy; Photosensitizing Agents; Risk Assessment; Skin Neoplasms; Treatment Outcome | 2021 |
Transcriptomic analysis identifies differences in gene expression in actinic keratoses after treatment with imiquimod and between responders and non responders.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aged, 80 and over; Biopsy; Female; Gene Expression; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Transcriptome; Treatment Outcome | 2021 |
Follicular extension of atypical keratinocytes predicts the resistance of actinic keratosis to topical imiquimod treatment: A single-center retrospective analysis.
Topics: Aminoquinolines; Humans; Imiquimod; Keratinocytes; Keratosis, Actinic; Retrospective Studies; Treatment Outcome | 2021 |
Patient assessment of 5-fluorouracil and imiquimod for the treatment of actinic keratoses: a retrospective study of real-world effectiveness.
Topics: Aminoquinolines; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Retrospective Studies; Treatment Outcome | 2022 |
Increased number of mast cells in the dermis in actinic keratosis lesions effectively treated with imiquimod.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Cell Count; Dermis; Dermoscopy; Erythema; Female; Humans; Imiquimod; Immunohistochemistry; Keratosis, Actinic; Ki-67 Antigen; Male; Mast Cells; Proto-Oncogene Proteins c-kit; Toll-Like Receptor 7; Treatment Outcome | 2017 |
Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece.
Topics: Aminoquinolines; Cost-Benefit Analysis; Diclofenac; Diterpenes; Greece; Humans; Imiquimod; Keratosis, Actinic; Quality-Adjusted Life Years | 2017 |
Patient-reported outcomes in topical field treatment of actinic keratosis in Swedish and Danish patients.
Topics: Administration, Topical; Aged; Aminoquinolines; Denmark; Diclofenac; Diterpenes; Drug Administration Schedule; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Patient Reported Outcome Measures; Patient Satisfaction; Quality of Life; Surveys and Questionnaires; Sweden | 2018 |
Imiquimoid 5%: In Pursuit of New Treatment Regimens for Actinic Keratosis.
Topics: Clinical Protocols; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic | 2018 |
Association between the clinical and histopathological classifications of actinic keratosis and the efficacy of topical imiquimod treatment.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Dose-Response Relationship, Drug; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Retrospective Studies; Skin; Treatment Outcome | 2018 |
A real-world, community-based cohort study comparing the effectiveness of topical fluorouracil versus topical imiquimod for the treatment of actinic keratosis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Cohort Studies; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2018 |
Various cold plasma devices for the treatment of actinic keratosis.
Topics: Adjuvants, Immunologic; Humans; Imiquimod; Keratosis, Actinic; Plasma Gases | 2018 |
Field-change actinic keratosis and immunosuppression: therapeutic options.
Topics: Humans; Imiquimod; Immunosuppression Therapy; Keratosis, Actinic; Photochemotherapy; Transplant Recipients | 2018 |
Pemphigus foliaceus induced by topical imiquimod treatment.
Topics: Adjuvants, Immunologic; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents; Complement C3; Humans; Imiquimod; Immunoglobulin G; Keratosis, Actinic; Male; Middle Aged; Pemphigus; Prednisone; Treatment Outcome | 2018 |
Evaluation of the treatment costs and duration of topical treatments for multiple actinic keratosis based on the area of the cancerization field and not on the number of lesions.
Topics: Administration, Topical; Aminolevulinic Acid; Cohort Studies; Cost of Illness; Diclofenac; Diterpenes; Drug Administration Schedule; Female; Fluorouracil; Health Care Costs; Humans; Imiquimod; Italy; Keratosis, Actinic; Male; Photochemotherapy; Precancerous Conditions; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2019 |
Two cases of erosive pustular dermatosis of the scalp occurring after topical 3.75% imiquimod for actinic keratoses.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Clobetasol; Dermatologic Agents; Drug Eruptions; Humans; Imiquimod; Keratosis, Actinic; Male; Scalp; Scalp Dermatoses; Treatment Outcome | 2019 |
Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study.
Topics: Administration, Cutaneous; Aged; California; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Comparative Effectiveness Research; Female; Fluorouracil; Humans; Imiquimod; Intention to Treat Analysis; Keratinocytes; Keratosis, Actinic; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Risk Factors; Skin Neoplasms | 2019 |
Efficacy of topical imiquimod 3.75% in the treatment of actinic keratosis of the scalp in immunosuppressed patients: our case series.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Erythema; Female; Humans; Imiquimod; Immunocompromised Host; Keratosis, Actinic; Male; Middle Aged; Scalp; Treatment Outcome | 2020 |
Imiquimod-induced widespread psoriasiform eruptions.
Topics: Administration, Cutaneous; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Imiquimod; Keratosis, Actinic; Psoriasis | 2019 |
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cost-Benefit Analysis; Cryotherapy; Dermatologic Agents; Diclofenac; Diterpenes; Electrocoagulation; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Laser Therapy; Photochemotherapy | 2019 |
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cryotherapy; Dermatologic Agents; Fluorouracil; Humans; Imiquimod; Immunocompromised Host; Immunosuppressive Agents; Keratosis, Actinic; Laser Therapy; Niacinamide; Phototherapy; Transplant Recipients | 2019 |
Addressing the Challenges of Treating Actinic Keratosis
Topics: Dermatologic Agents; Disease Progression; Diterpenes; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy | 2019 |
Aldara activates TLR7-independent immune defence.
Topics: Aminoquinolines; Animals; Apoptosis; Carcinoma, Basal Cell; Cell Proliferation; Cells, Cultured; Cytokines; Epidermis; Gene Expression Regulation; Humans; Imiquimod; Immunity; Inflammasomes; Interferon Type I; Keratinocytes; Keratosis, Actinic; Mice; Models, Immunological; Neutrophil Infiltration; RNA, Messenger; Skin Neoplasms; Toll-Like Receptor 7; Up-Regulation | 2013 |
Key Opinion Leader (KOL) Consensus for actinic keratosis management in Italy: the AKTUAL Workshop.
Topics: Aminoquinolines; Carcinoma, Squamous Cell; Case Management; Clinical Trials as Topic; Cryosurgery; Diagnosis, Differential; Diclofenac; Disease Management; Disease Progression; Diterpenes; Fluorouracil; Humans; Imiquimod; Italy; Keratosis, Actinic; Laser Therapy; Neoplasms, Radiation-Induced; Photochemotherapy; Practice Guidelines as Topic; Skin Neoplasms; Sunscreening Agents; United Kingdom; United States; Watchful Waiting | 2013 |
Development of recalcitrant skin ulcers as a side-effect of treatment with topical 5% imiquimod cream: report of two cases.
Topics: Adjuvants, Immunologic; Aged; Aminoquinolines; Humans; Imiquimod; Keratosis, Actinic; Male; Skin Cream; Skin Ulcer; Withholding Treatment | 2014 |
Physicians' opinions and clinical practice patterns for actinic keratosis management in Italy.
Topics: Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Attitude of Health Personnel; Carcinoma in Situ; Carcinoma, Squamous Cell; Cryotherapy; Curettage; Dermatology; Dermoscopy; Diclofenac; Disease Management; Guideline Adherence; Humans; Imiquimod; Italy; Keratosis, Actinic; Laser Therapy; Neoplasms, Multiple Primary; Neoplasms, Radiation-Induced; Photochemotherapy; Photosensitivity Disorders; Physicians; Practice Guidelines as Topic; Practice Patterns, Physicians'; Skin Neoplasms; Sunlight; Surveys and Questionnaires | 2014 |
Relapsed actinic keratosis evaluation: an observational Italian multicenter prospective study. Does gender have a role?
Topics: Adult; Aged; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cohort Studies; Cryotherapy; Curettage; Diclofenac; Female; Humans; Hyaluronic Acid; Imiquimod; Italy; Keratosis, Actinic; Male; Middle Aged; Patient Compliance; Photochemotherapy; Prospective Studies; Protective Clothing; Recurrence; Remission Induction; Sex Factors; Sunscreening Agents | 2014 |
Identification of an occupational skin disease according to German § 9 Par. 2 SGB VII during topical therapy with imiquimod.
Topics: Adjuvants, Immunologic; Aged; Agricultural Workers' Diseases; Aminoquinolines; Humans; Imiquimod; Keratosis, Actinic; Male; Occupational Diseases; Practice Guidelines as Topic; Terminology as Topic | 2014 |
Visualization and treatment of subclinical actinic keratoses with topical imiquimod 5% cream: an observational study.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Skin Cream; Skin Neoplasms; Treatment Outcome | 2014 |
Recruitment of plasmacytoid dendritic cells to skin regulates treatment responsiveness of actinic keratosis to imiquimod.
Topics: Adjuvants, Immunologic; Aminoquinolines; Biopsy; Cytokines; Dendritic Cells; Humans; Imiquimod; Inflammation; Interferon-alpha; Keratosis, Actinic; RNA, Messenger; Skin; Toll-Like Receptor 7; Wound Healing | 2014 |
Histologic features mimicking mycosis fungoides induced by imiquimod, 5%: a potential pitfall for dermatopathologists.
Topics: Adjuvants, Immunologic; Aged, 80 and over; Aminoquinolines; Drug Eruptions; Humans; Imiquimod; Keratosis, Actinic; Male; Mycosis Fungoides; Skin Diseases | 2014 |
From a new vision of actinic keratosis to imiquimod 3.75%, the new treatment standard. Introduction.
Topics: Adjuvants, Immunologic; Aminoquinolines; Humans; Imiquimod; Keratosis, Actinic | 2015 |
Lmax and imiquimod 3.75% in daily clinical practice.
Topics: Adjuvants, Immunologic; Aminoquinolines; Cohort Studies; Humans; Imiquimod; Keratosis, Actinic; United Kingdom | 2015 |
Field cancerization: from molecular basis to selective field-directed management of actinic keratosis.
Topics: Administration, Topical; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Skin Neoplasms | 2015 |
Imiquimod induces sustained remission of actinic damage: a case report spanning one decade of observation.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Skin Neoplasms | 2015 |
Development of nanovesicular systems for dermal imiquimod delivery: physicochemical characterization and in vitro/in vivo evaluation.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Animals; Chemistry, Pharmaceutical; Drug Carriers; Drug Delivery Systems; Drug Stability; Humans; Imiquimod; In Vitro Techniques; Keratosis, Actinic; Liposomes; Male; Microscopy, Confocal; Nanocapsules; Particle Size; Permeability; Rats; Rats, Sprague-Dawley; Skin; Sus scrofa | 2015 |
Actinic keratosis: a cross-sectional study of disease characteristics and treatment patterns in Danish dermatology clinics.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Cross-Sectional Studies; Cryotherapy; Denmark; Dermatology; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Outpatient Clinics, Hospital; Photochemotherapy; Photosensitizing Agents; Practice Patterns, Physicians'; Private Practice; Sex Factors; Skin Neoplasms | 2016 |
Real-life Data on Patient Characteristics, Cost and Effectiveness of Field-directed Treatment for Actinic Keratoses: An Observational Study.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Aminoquinolines; Cost-Benefit Analysis; Dermatologic Agents; Drug Costs; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Netherlands; Patient Preference; Photochemotherapy; Photosensitizing Agents; Remission Induction; Severity of Illness Index; Time Factors; Treatment Outcome | 2016 |
Imiquimod 3.75% in actinic keratosis: efficacy in patients with and without rest periods during treatment.
Topics: Aminoquinolines; Double-Blind Method; Drug Administration Schedule; Humans; Imiquimod; Keratosis, Actinic | 2016 |
Methods and Results Report - Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis -International League of Dermatological Societies in cooperation with the European Dermatology Forum.
Topics: Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Cryotherapy; Curettage; Cyclooxygenase Inhibitors; Diclofenac; Diterpenes; Evidence-Based Medicine; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Laser Therapy; Lasers, Gas; Photochemotherapy | 2015 |
Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aminoquinolines; Cohort Studies; Dermatologic Agents; Face; Female; Follow-Up Studies; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Scalp; Treatment Outcome | 2018 |
Use of the back of the hands to apply imiquimod.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Hand; Humans; Imiquimod; Keratosis, Actinic; Treatment Outcome | 2016 |
Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aminoquinolines; Double-Blind Method; Face; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Randomized Controlled Trials as Topic; Scalp; Treatment Outcome | 2016 |
Case of Japanese Hermansky-Pudlak syndrome patient with deeply invasive squamous cell carcinoma and multiple lesions of actinic keratosis on the face and neck.
Topics: Administration, Cutaneous; Adult; Carcinoma, Squamous Cell; Face; Hermanski-Pudlak Syndrome; Humans; Imiquimod; Japan; Keratosis, Actinic; Male; Membrane Proteins; Neck; Skin; Skin Neoplasms; Sunlight; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Imiquimod-induced vitiligo-like depigmentation over multiple solar keratosis in a patient with vitiligo.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Keratosis, Actinic; Male; Vitiligo | 2017 |
Pityriasis rubra pilaris exacerbation with topical use of imiquimod.
Topics: Administration, Topical; Aged; Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Keratosis, Actinic; Male; Pityriasis Rubra Pilaris | 2008 |
Eruptive keratoacanthoma following topical imiquimod for in situ squamous cell carcinoma of the skin in a renal transplant recipient.
Topics: Aged, 80 and over; Aminoquinolines; Bowen's Disease; Carcinoma, Squamous Cell; Female; Humans; Imiquimod; Keratoacanthoma; Keratosis, Actinic; Kidney Transplantation; Skin Neoplasms | 2008 |
An economic evaluation of topical treatments for actinic keratosis.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Cost-Benefit Analysis; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Models, Economic; Photochemotherapy; Photosensitizing Agents; Treatment Outcome; United Kingdom | 2009 |
A case of imiquimod-induced alopecia.
Topics: Adjuvants, Immunologic; Alopecia; Aminoquinolines; Biopsy; Female; Humans; Imiquimod; Keratosis, Actinic; Middle Aged; Ointments | 2010 |
Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Carcinoma in Situ; Drug Monitoring; Humans; Imiquimod; Keratosis, Actinic; Microscopy, Confocal; Middle Aged; Treatment Outcome | 2010 |
Erosive pustular dermatosis of the scalp following treatment with topical imiquimod for actinic keratosis.
Topics: Administration, Topical; Aged, 80 and over; Aminoquinolines; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Imiquimod; Immunohistochemistry; Keratosis, Actinic; Male; Risk Assessment; Scalp Dermatoses; Severity of Illness Index; Skin Diseases, Papulosquamous | 2009 |
The use of imiquimod in the treatment of periocular tumours.
Topics: Administration, Topical; Aged; Aminoquinolines; Antineoplastic Agents; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Eyelid Neoplasms; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Ophthalmic Solutions; Retrospective Studies; Skin Neoplasms; Treatment Outcome | 2010 |
Current management of actinic keratoses.
Topics: Administration, Cutaneous; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Squamous Cell; Diclofenac; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Skin Neoplasms | 2010 |
[Imiquimod cream. A cream to use with precaution].
Topics: Administration, Topical; Adult; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Condylomata Acuminata; Drug Eruptions; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Skin Neoplasms; Treatment Outcome | 2010 |
Detection and treatment of preclinical actinic keratoses (PAK).
Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Squamous Cell; Facial Dermatoses; Female; Humans; Imiquimod; Keratosis, Actinic; Middle Aged; Neoplasms, Radiation-Induced; Precancerous Conditions; Skin Aging | 2010 |
Development of subacute cutaneous lupus erythematosus associated with the use of imiquimod to treat actinic keratoses.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Autoimmune Diseases; Female; Humans; Imiquimod; Keratosis, Actinic; Lupus Erythematosus, Cutaneous; Middle Aged; Retinitis; Severity of Illness Index | 2010 |
Agreement on the clinical diagnosis and management of cutaneous squamous neoplasms.
Topics: Algorithms; Aminoquinolines; Biopsy; Carcinoma in Situ; Carcinoma, Squamous Cell; Cryosurgery; Curettage; Dermatology; Diagnosis, Differential; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Mohs Surgery; Photochemotherapy; Precancerous Conditions; Reproducibility of Results; Skin Neoplasms; Terminology as Topic; United States | 2010 |
The ophthalmic side-effects of imiquimod therapy in the management of periocular skin lesions.
Topics: Administration, Topical; Aged; Aminoquinolines; Antineoplastic Agents; Bowen's Disease; Carcinoma, Basal Cell; Conjunctivitis; Erythema; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Retrospective Studies; Skin Neoplasms; Treatment Outcome | 2011 |
Lupus erythematosus-like imiquimod reaction: a diagnostic pitfall.
Topics: Adjuvants, Immunologic; Aged; Aminoquinolines; Diagnosis, Differential; Humans; Imiquimod; Immunity, Cellular; Keratosis, Actinic; Male; Skin Diseases | 2011 |
Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system.
Topics: Administration, Topical; Aminolevulinic Acid; Aminoquinolines; Cost-Benefit Analysis; Decision Trees; Delivery of Health Care; Diclofenac; Health Care Costs; Humans; Imiquimod; Italy; Keratosis, Actinic | 2010 |
Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model.
Topics: Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Cost-Benefit Analysis; Data Interpretation, Statistical; Decision Trees; Humans; Imiquimod; Keratosis, Actinic; Models, Economic; Photochemotherapy; Photosensitizing Agents; Quality-Adjusted Life Years; United Kingdom | 2010 |
Actinic keratosis. Patient-based approaches to adverse event management.
Topics: Administration, Topical; Aminoquinolines; Combined Modality Therapy; Cryotherapy; Dermatologic Agents; Diclofenac; Electrosurgery; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photosensitizing Agents | 2010 |
What's new in the treatment of actinic keratoses?
Topics: Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Cryotherapy; Diterpenes; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Skin Neoplasms | 2011 |
Lupus erythematosus-like reaction in imiquimod-treated skin: a report of 2 cases.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Dermatitis; Diagnosis, Differential; Female; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Keratosis, Actinic; Lupus Erythematosus, Systemic; Male; Skin Neoplasms | 2011 |
Imiquimod and lymphatic field clearance: a new hypothesis based on a remote immune action on skin cancer.
Topics: Administration, Cutaneous; Aged; Aminoquinolines; Antineoplastic Agents; Biopsy; Carcinoma, Basal Cell; Humans; Imiquimod; Immunologic Factors; Keratosis, Actinic; Lymphatic System; Male; Ointments; Skin Neoplasms; Treatment Outcome | 2011 |
Severe systemic reaction to topical imiquimod.
Topics: Administration, Cutaneous; Aged; Aminoquinolines; Dehydration; Dizziness; Drug Eruptions; Female; Humans; Imiquimod; Keratosis, Actinic; Nausea; Severity of Illness Index; Vomiting | 2011 |
Dermatoscopy for monitoring treatment of actinic keratosis with imiquimod.
Topics: Adjuvants, Immunologic; Aged; Aminoquinolines; Dermoscopy; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged | 2012 |
Treatment of actinic keratoses with 5% topical imiquimod: a multicenter prospective observational study from 93 Austrian office-based dermatologists.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Austria; Dermatology; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Patient Education as Topic; Patient Satisfaction; Time Factors; Treatment Outcome | 2012 |
Treatment-refractory actinic keratoses successfully treated using simultaneous combination topical 5-fluorouracil cream and imiquimod cream: a case-control study.
Topics: Aged; Aged, 80 and over; Aminoquinolines; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Agents; Case-Control Studies; Chi-Square Distribution; Cryosurgery; Drug Therapy, Combination; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Retrospective Studies; Treatment Failure | 2012 |
Patients' perceptions of topical treatments of actinic keratosis.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Diclofenac; Female; Fluorouracil; Gels; Humans; Imiquimod; Keratosis, Actinic; Male; Middle Aged; Patient Acceptance of Health Care; Photochemotherapy; Precancerous Conditions; Skin Cream | 2014 |